
    
      Contrast enhancement with Gadolinium will be evaluated to assess its efficacy for diagnosis
      and exclusion of pulmonary embolism in a patient who previously would not have been
      investigated with CTPA due to an underlying allergy to contrast or other contraindication. If
      this proves beneficial, it will allow such patients to be investigated successfully with CTPA
    
  